SPOTLIGHT -
New Drug Review: Spravato
Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
What Pharmacists Need to Know About Lofexidine
FDA approves lofexidine for opioid withdrawal symptoms.
